Repligen Corp (RGEN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Repligen Corp (RGEN)

RGEN 166.92

+0.3%

Jan 9 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Curtis E. Bemis who wrote (225)	5/22/2000 12:47:00 PM
From: Cheryl Galt	Read Replies (1) of 395

Curtis, it looks like Repligen is side-stepping an impasse in its CTLA4 patent dispute with BMS, and is now making an attempt "upstream." IMO this is significant and hopeful. I'm no longer on the sidelines; took a position Friday morning. I'm hoping to hear opinions from our SI bio-experts on this subject. ---------------------- IMO, Key points of the May 18 press release: repligen.com 1) RGEN acquired rights to a CTLA4-Ig patent application from Tolerance Therapeutics - formed by Dr. Jefferey Bluestone, the first investigator to demonstrate that CTLA4-Ig was effective in an animal model of disease - seminal paper in Science -- 1992, v. 257, pp. 789-792 2) If a patent is issued, it will be jointly owned by Repligen and Bristol-Myers, and both parties will have unrestricted rights to practice the invention -- without obligation to the other. 3) Repligen is currently planning expanded testing of CTLA4-Ig in Phase 2 clinical trials. ---------------------------------- PS - @ 5.75, RGEN is one of the few stocks holding up in today's tech bloodbath. ....... so far anyway ...

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next